Lenacapavir and oral HIV pre-exposure prophylaxis (PrEP) are options for reducing the risk of acquiring HIV, but they differ in how they are administered and how often they are taken. Lenacapavir is a long-acting injectable medication approved for HIV prevention in certain countries, while oral PrEP typically involves taking a preventive medication daily. Understanding their dosing schedules, effectiveness, safety considerations, and access requirements can help people discuss suitable prevention strategies with healthcare professionals. Both approaches require appropriate HIV testing and medical guidance. The choice depends on individual health circumstances, preferences, availability, and the recommendations of qualified healthcare providers.
Lenacapavir works by targeting the HIV capsid, a protein structure that helps the virus reproduce and spread within the body. For prevention, it is administered through subcutaneous injections on a six-month schedule after an initial dosing phase. Oral PrEP commonly uses medications containing emtricitabine and tenofovir, which interfere with processes HIV needs to establish infection. These tablets are generally taken daily. The US Food and Drug Administration approved injectable lenacapavir for HIV prevention in June 2025, although approval and availability vary by country. Administration: Lenacapavir involves injections, while oral PrEP involves taking tablets.
Dosing schedule: Lenacapavir maintenance injections are given every six months. Common oral PrEP regimens require consistent daily use.
Adherence: Lenacapavir may suit people who find daily medication difficult to maintain. Oral PrEP provides flexibility for those who prefer tablets.
Effectiveness: Both approaches can substantially reduce HIV acquisition risk when used appropriately. Clinical trials found very high preventive efficacy for lenacapavir, although results from individual trials should not be interpreted as a guarantee of protection for every person. +1
Both forms of PrEP require medical assessment before treatment begins and ongoing follow-up. Healthcare professionals must confirm that a person does not have HIV before prescribing PrEP, because preventive medication alone is not an adequate treatment regimen for an existing HIV infection. Testing schedules and additional assessments depend on the medication used and the person's circumstances. Important considerations include:
Side effects: Lenacapavir can cause injection-site reactions, including swelling, pain, or lumps. Oral PrEP may cause nausea, headache, or other side effects. Some oral regimens also require monitoring of kidney function.
HIV testing: Appropriate blood-based HIV testing is necessary before starting PrEP and at recommended follow-up visits.
Drug interactions: Lenacapavir can interact with certain medications, so a clinician should review current prescriptions and other medicines.
Access and cost: Availability, eligibility requirements, and affordability differ across countries and healthcare systems.
Ongoing protection: Missed injections, missed tablets, or discontinuation can reduce protection. People changing or stopping PrEP should discuss an appropriate prevention plan with their healthcare provider.
Lenacapavir and oral HIV PrEP offer different approaches to preventing HIV infection. Lenacapavir reduces the need for frequent dosing, while oral PrEP remains an established option for people who prefer daily medication. The most appropriate choice depends on medical history, individual preferences, potential drug interactions, affordability, and local availability. Consultation with a qualified healthcare professional can help determine which option fits an individual's prevention needs. This article is intended for informational and educational purposes only and does not promote or sell medical products or services.